ST. LOUIS, Nov. 13, 2024 (GLOBE NEWSWIRE) — Curium, a world leader in nuclear medicine, announced today that its ECLIPSE trial met its primary endpoint. ECLIPSE is a pivotal Phase 3, multi-center, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback